Other Information.
−Removed: Rule 10b5-1 Trading Arrangements
−Removed: On August 13, 2025 , Sandip Kapadia , Chief Financial Officer and Chief Administrative Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 50,000 shares of the Company’s common stock related to the exercise of options, (ii) up to 20,961 shares of the Company’s common stock related to the September 30, 2025 vesting of restricted stock units previously granted, and (iii) an indeterminable number of shares of the Company’s common stock that will depend on the number of shares sold to cover tax withholding obligations in connection with the vesting of 8,538 restricted stock units previously granted, beginning on January 15, 2026 and continuing until June 30, 2026 .
+Added: (c) During the three months ended March 31, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement” and/or “ non-Rule 10b5-1 trading arrangement,” as each term is defined in item 408 of Regulation S-K.
Incorporated by Reference
7 unchanged sentences
August 21, 2020
+Added: Executive Employment Agreement between Harmony Biosciences Management, Inc.
+Added: and Peter Anastasiou, dated April 2, 2026.
+Added: April 2, 2026
+Added: Separation Agreement by and between Harmony Biosciences Holdings, Inc., Harmony Biosciences Management, Inc., and Sandip Kapadia, dated April 14, 2026.
+Added: April 14, 2026
+Added: Executive Employment Agreement by and between Harmony Biosciences Management, Inc.
+Added: and Glenn Reicin, dated April 14, 2026.
+Added: April 14, 2026
Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial statements from the Company ’ s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, formatted in Inline XBRL:
+Added: The following financial statements from the Company ’ s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, formatted in Inline XBRL:
(i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders ’ Equity and (vi) Notes to Financial Statements, tagged as blocks of text and including detailed tags.
4 unchanged sentences
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
+Added: Indicates management contract or compensatory plan or arrangement.
Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K.
5 unchanged sentences
President, Chief Executive Officer and Director (principal executive officer)
−Removed: November 4, 2025
−Removed: /s/ Sandip Kapadia
−Removed: Sandip Kapadia
−Removed: Chief Financial Officer and Chief Administrative Officer (principal financial officer)
−Removed: November 4, 2025
+Added: /s/ Glenn Reicin
+Added: Chief Financial Officer (principal financial officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.